The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone Resorption

Although multiple hormones and cytokines regulate various aspects of osteoclast formation, the final two effectors are osteoprotegerin ligand (OPG‐L)/osteoclast differentiation factor (ODF), a recently cloned member of the tumor necrosis factor superfamily, and macrophage colony–stimulating factor. OPG‐L/ODF is produced by osteoblast lineage cells and exerts its biological effects through binding to its receptor, osteoclast differentiation and activation receptor (ODAR)/receptor activator of NF‐κB (RANK), on osteoclast lineage cells, in either a soluble or a membrane‐bound form, the latter of which requires cell‐to‐cell contact. Binding results in rapid differentiation of osteoclast precursors in bone marrow to mature osteoclasts and, at higher concentrations, in increased functional activity and reduced apoptosis of mature osteoclasts. The biological activity of OPG‐L/ODF is neutralized by binding to osteoprotegerin (OPG)/osteoclastogenesis inhibitory factor (OCIF), a member of the TNF‐receptor superfamily that also is secreted by osteoblast lineage cells. The biological importance of this system is underscored by the induction in mice of severe osteoporosis by targeted ablation of OPG/OCIF and by the induction of osteopetrosis by targeted ablation of OPG‐L/ODF or overexpression of OPG/OCIF. Thus, osteoclast formation may be determined principally by the relative ratio of OPG‐L/ODF to OPG/OCIF in the bone marrow microenvironment, and alterations in this ratio may be a major cause of bone loss in many metabolic disorders, including estrogen deficiency and glucocorticoid excess. That changes in but two downstream cytokines mediate the effects of large numbers of upstream hormones and cytokines suggests a regulatory mechanism for osteoclastogenesis of great efficiency and elegance.

[1]  B. Aggarwal,et al.  Characterization of the Intracellular Domain of Receptor Activator of NF-κB (RANK) , 1998, The Journal of Biological Chemistry.

[2]  S. Reddy,et al.  Control of osteoclast differentiation. , 1998, Critical reviews in eukaryotic gene expression.

[3]  R. Kitazawa,et al.  Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. , 1994, The Journal of clinical investigation.

[4]  G. Mundy,et al.  Estrogen promotes apoptosis of murine osteoclasts mediated by TGF–β , 1996, Nature Medicine.

[5]  R. Steinman,et al.  TRANCE (Tumor Necrosis Factor [TNF]-related Activation-induced Cytokine), a New TNF Family Member Predominantly Expressed in T cells, Is a Dendritic Cell–specific Survival Factor , 1997, The Journal of experimental medicine.

[6]  S. Mochizuki,et al.  Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. , 1998, Endocrinology.

[7]  S. Morony,et al.  OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.

[8]  A. Di Giorgio,et al.  Alterations of bone turnover and bone mass at different skeletal sites due to pure glucocorticoid excess: study in eumenorrheic patients with Cushing's syndrome. , 1998, The Journal of clinical endocrinology and metabolism.

[9]  B. Riggs,et al.  Osteoclasts and transforming growth factor-beta: estrogen-mediated isoform-specific regulation of production. , 1996, Endocrinology.

[10]  E. Barengolts,et al.  Osteoporosis and Coronary Atherosclerosis in Asymptomatic Postmenopausal Women , 1998, Calcified Tissue International.

[11]  B. Riggs,et al.  Modulation of Transforming Growth Factor-β Production in Normal Human Osteoblast-Like Cells by 17β-Estradiol and Parathyroid Hormone , 1991 .

[12]  Roodman Gd Advances in bone biology : The osteoclast , 1996 .

[13]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[14]  D. Dempster Perspectives bone histomorphometry in glucocorticoid‐induced osteoporosis , 1989 .

[15]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[16]  L. Hood,et al.  OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. , 1998, Journal of immunology.

[17]  C. Thompson,et al.  Tumor necrosis factor receptor-associated factors (TRAFs)--a family of adapter proteins that regulates life and death. , 1998, Genes & development.

[18]  M. Kumegawa,et al.  Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts. , 1998, Biochemical and biophysical research communications.

[19]  H. Broxmeyer,et al.  Increased osteoclast development after estrogen loss: mediation by interleukin-6. , 1992, Science.

[20]  C. Ohlsson,et al.  Tumor Necrosis Factor-α and -β Upregulate the Levels of Osteoprotegerin mRNA in Human Osteosarcoma MG-63 Cells , 1998 .

[21]  N. Nagata,et al.  Transforming Growth Factor-β1 Increases mRNA Levels of Osteoclastogenesis Inhibitory Factor in Osteoblastic/Stromal Cells and Inhibits the Survival of Murine Osteoclast-like Cells , 1998 .

[22]  R. Kimble,et al.  The Functional Block of TNF but Not of IL‐6 Prevents Bone Loss in Ovariectomized Mice , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[23]  Roberto Pacifici,et al.  Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[24]  B. Riggs,et al.  The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. , 1999, Molecular endocrinology.

[25]  S. Morony,et al.  TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. , 1999, Genes & development.

[26]  Brian R. Wong,et al.  TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells* , 1997, The Journal of Biological Chemistry.

[27]  C. Ohlsson,et al.  Regulation of osteoprotegerin mRNA levels by prostaglandin E2 in human bone marrow stroma cells. , 1998, Biochemical and biophysical research communications.

[28]  E. Wagner,et al.  Bone and haematopoietic defects in mice lacking c-fos , 1992, Nature.

[29]  B. Riggs,et al.  Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. , 1998, Biochemical and biophysical research communications.

[30]  K. Miyake,et al.  Establishment and characterization of an immortal macrophage-like cell line inducible to differentiate to osteoclasts. , 1998, Biochemical and biophysical research communications.

[31]  R. Jilka,et al.  Cytokines, bone remodeling, and estrogen deficiency: a 1998 update. , 1998, Bone.

[32]  H. Kawaguchi,et al.  Ovariectomy enhances and estrogen replacement inhibits the activity of bone marrow factors that stimulate prostaglandin production in cultured mouse calvariae. , 1995, The Journal of clinical investigation.

[33]  D. Lacey,et al.  Printed in U.S.A. Copyright © 1999 by The Endocrine Society Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in , 2022 .

[34]  G. Gronowicz,et al.  Glucocorticoids stimulate resorption in fetal rat parietal bones in vitro , 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[35]  N. Udagawa,et al.  Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. , 1998, Biochemical and biophysical research communications.

[36]  H. Genant,et al.  A Preliminary Evaluation of the Lunar Expert‐XL for Bone Densitometry and Vertebral Morphometry , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[37]  P. Young,et al.  Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. , 1997, Gene.

[38]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[39]  C. Dinarello,et al.  Biologic basis for interleukin-1 in disease. , 1996, Blood.

[40]  E. Jimi,et al.  Regulation of Osteoclast Function , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[41]  S. Morony,et al.  Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[42]  B. Spiegelman,et al.  Pleiotropic effects of a null mutation in the c-fos proto-oncogene , 1992, Cell.

[43]  P. Kelly,et al.  Quantitative microradiographic study of bone remodeling in Cushing's syndrome. , 1966, Metabolism: clinical and experimental.

[44]  D. Lacey,et al.  Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. , 1999, Endocrinology.

[45]  R. Steinman,et al.  The TRAF Family of Signal Transducers Mediates NF-κB Activation by the TRANCE Receptor* , 1998, The Journal of Biological Chemistry.

[46]  S. Ikuyama,et al.  Glucocorticoid-induced osteoporosis: pathogenesis and management , 2000, Journal of Bone and Mineral Metabolism.

[47]  T. Komori,et al.  Potential role of cbfa1, an essential transcriptional factor for osteoblast differentiation, in osteoclastogenesis: regulation of mRNA expression of osteoclast differentiation factor (ODF). , 1998, Biochemical and biophysical research communications.

[48]  John C. Lee,et al.  Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL* , 1998, The Journal of Biological Chemistry.

[49]  T. Martin,et al.  Modulation of osteoclast differentiation. , 1992, Endocrine reviews.

[50]  M. Goto,et al.  Characterization of Structural Domains of Human Osteoclastogenesis Inhibitory Factor* , 1998, The Journal of Biological Chemistry.

[51]  G. Cheng,et al.  An Intact Zinc Ring Finger Is Required for Tumor Necrosis Factor Receptor-associated Factor-mediated Nuclear Factor-κB Activation but Is Dispensable for c-Jun N-terminal Kinase Signaling* , 1998, The Journal of Biological Chemistry.

[52]  U. Lerner,et al.  Stimulation of neonatal mouse calvarial bone resorption by the glucocorticoids hydrocortisone and dexamethasone , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[53]  B. Aggarwal,et al.  Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. , 1999, The Journal of biological chemistry.

[54]  K. Ikeda,et al.  Immunological Characterization of Circulating Osteoprotegerin/Osteoclastogenesis Inhibitory Factor: Increased Serum Concentrations in Postmenopausal Women with Osteoporosis , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[55]  H. Yasuda,et al.  RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. , 1998, Biochemical and biophysical research communications.

[56]  F. Ross,et al.  Estrogen Deficiency Increases the Ability of Stromal Cells to Support Murine Osteoclastogenesis via an Interleukin-1and Tumor Necrosis Factor-mediated Stimulation of Macrophage Colony-stimulating Factor Production* , 1996, The Journal of Biological Chemistry.

[57]  S. Morony,et al.  osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.

[58]  B. Riggs,et al.  Human giant cell tumors of the bone (osteoclastomas) are estrogen target cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[59]  S. Mochizuki,et al.  Hypocalcemic effect of osteoclastogenesis inhibitory factor/osteoprotegerin in the thyroparathyroidectomized rat. , 1998, Endocrinology.

[60]  J. Caamaño,et al.  Osteopetrosis in mice lacking NF-κB1 and NF-κB2 , 1997, Nature Medicine.

[61]  Li Sun,et al.  Mode of Action of Interleukin-6 on Mature Osteoclasts. Novel Interactions with Extracellular Ca2+ Sensing in the Regulation of Osteoclastic Bone Resorption , 1998, The Journal of cell biology.

[62]  B. Aggarwal,et al.  Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase. , 1998, The Journal of biological chemistry.

[63]  R. Kimble,et al.  Monocytic secretion of interleukin-1 receptor antagonist in normal and osteoporotic women: effects of menopause and estrogen/progesterone therapy. , 1993, The Journal of clinical endocrinology and metabolism.

[64]  N. Udagawa,et al.  Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. , 1998, Biochemical and biophysical research communications.

[65]  G. Roodman,et al.  Advances in bone biology: the osteoclast. , 1996, Endocrine reviews.

[66]  S. Mochizuki,et al.  Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor. , 1998, Biochemical and biophysical research communications.

[67]  D. Lacey,et al.  Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells , 1999 .

[68]  W. Dougall,et al.  The Involvement of Multiple Tumor Necrosis Factor Receptor (TNFR)-associated Factors in the Signaling Mechanisms of Receptor Activator of NF-κB, a Member of the TNFR Superfamily* , 1998, The Journal of Biological Chemistry.

[69]  T. Suda Modulation of osteoclast differentiation [published erratum appears in Endocr Rev 1992 May;13(2):191] , 1992 .

[70]  T. Martin,et al.  A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. , 1998, Endocrinology.

[71]  R. Dubose,et al.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.

[72]  I. Reid Glucocorticoid osteoporosis--mechanisms and management. , 1997, European journal of endocrinology.

[73]  H. Yasuda,et al.  Structure of the mouse osteoclastogenesis inhibitory factor (OCIF) gene and its expression in embryogenesis. , 1998, Gene.

[74]  T. Komori,et al.  Excessive extramedullary hematopoiesis in Cbfa1-deficient mice with a congenital lack of bone marrow. , 1999, Biochemical and biophysical research communications.

[75]  S. Mochizuki,et al.  Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. , 1997, Biochemical and biophysical research communications.

[76]  T. Steinberg,et al.  Impaired intramembranous bone formation in connexin43 null mice , 1998 .

[77]  K. Chihara,et al.  Dexamethasone Stimulates Osteoclast‐like Cell Formation by Directly Acting on Hemopoietic Blast Cells and Enhances Osteoclast‐like Cell Formation Stimulated by Parathyroid Hormone and Prostaglandin E2 , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[78]  B. L. Riggs,et al.  A Unitary Model for Involutional Osteoporosis: Estrogen Deficiency Causes Both Type I and Type II Osteoporosis in Postmenopausal Women and Contributes to Bone Loss in Aging Men , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[79]  C. Ohlsson,et al.  Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids. , 1998, The Journal of endocrinology.

[80]  S. Mochizuki,et al.  Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy. , 1998, Bone.

[81]  K. Ikeda,et al.  Transforming Growth Factor-β Stimulates the Production of Osteoprotegerin/Osteoclastogenesis Inhibitory Factor by Bone Marrow Stromal Cells* , 1998, The Journal of Biological Chemistry.

[82]  L. Lum,et al.  Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. , 1999, The Journal of biological chemistry.

[83]  K. Sjögren,et al.  Osteoprotegerin mRNA is increased by interleukin-1 alpha in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells. , 1998, Biochemical and biophysical research communications.

[84]  S. Mochizuki,et al.  Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast. , 1998, Biochemical and biophysical research communications.

[85]  L. Lum,et al.  Evidence for a Role of a Tumor Necrosis Factor-α (TNF-α)-converting Enzyme-like Protease in Shedding of TRANCE, a TNF Family Member Involved in Osteoclastogenesis and Dendritic Cell Survival* , 1999, The Journal of Biological Chemistry.

[86]  B. Kwon,et al.  TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[87]  A. Parfitt,et al.  Theoretical perspective: A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates , 1996 .

[88]  K Yano,et al.  Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. , 1998, Biochemical and biophysical research communications.

[89]  D. Lacey,et al.  The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts , 1999, The Journal of cell biology.

[90]  C. O’Brien,et al.  STAT3 Activation in Stromal/Osteoblastic Cells Is Required for Induction of the Receptor Activator of NF-κB Ligand and Stimulation of Osteoclastogenesis by gp130-utilizing Cytokines or Interleukin-1 but Not 1,25-Dihydroxyvitamin D3 or Parathyroid Hormone* , 1999, The Journal of Biological Chemistry.

[91]  G. Roodman,et al.  Transforming growth factor beta inhibits formation of osteoclast-like cells in long-term human marrow cultures. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[92]  G. Mundy,et al.  Transforming growth factor beta inhibits bone resorption in fetal rat long bone cultures. , 1988, The Journal of clinical investigation.

[93]  R. Jilka,et al.  Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. , 1995, The New England journal of medicine.

[94]  E. Hammond,et al.  The Cell-surface Form of Colony-stimulating Factor-1 Is Regulated by Osteotropic Agents and Supports Formation of Multinucleated Osteoclast-like Cells* , 1998, The Journal of Biological Chemistry.